Loading stock data…
Viking Therapeutics (VKTX)
$34.79-0.60 (-1.70%)
Market ClosedLast close Jul 24
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viking Therapeutics, Inc. in the Healthcare sector is trading at $34.79 with a market capitalization of $3.4B. Wall Street consensus targets $92.58 (19 analysts), implying a +166.1% move over the next 12 months. The stock is currently 19% below its 52-week high of $43.15, remaining 3.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +166.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$164.13M↑ | -$164.74M↓ | -$98.56M↓ | -$74.57M↓ | -$55.47M |
| Net Income | -$158.32M↓ | -$157.66M↓ | -$90.79M↓ | -$65.56M↓ | -$45.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-94.11%
Volume
Today's trading volume
1.82M
Recent News
Viking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy News
Viking Therapeutics stock has delivered a very large 5 year return, yet its current valuation checks lean expensive, setting up a clear tension between strong past gains and what the current price implies about future expectations. Viking Therapeutics has returned roughly 4.8x over the past 5 years, which means a lot of optimism is already embedded in the share price. Excitement around new diabetes and metabolic therapies can support high expectations, but execution risk in advancing and...
Viking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Comes Into View
Viking Therapeutics (NasdaqCM:VKTX) has appointed Dorothy Gemmell to its Board of Directors. Gemmell brings extensive experience in healthcare commercialization and leadership at large healthcare organizations. Viking Therapeutics, trading at $35.39, has drawn attention with the appointment of Dorothy Gemmell to its board, adding a leader with deep commercialization experience to its governance mix. The stock has delivered very large gains over the past 5 years and is up 158.1% over 3...
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Viking Therapeutics, Inc. (VKTX) reached $35.39 at the closing of the latest trading day, reflecting a -5.15% change compared to its last close.
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
Viking's latest program seeks to push the envelope in weight loss efficacy.
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."
Wall Street analysts are highly bullish on Viking Therapeutics, not least because of its promising weight-loss drug, with ongoing and upcoming phase 3 trials.